Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma

Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance

(2019) Jonathan K. M. Lim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

(2019) Jude Canon et al.   NATURE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase

(2018) Dana M. Gwinn et al.   CANCER CELL

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

(2018) Chiara Ambrogio et al.   CELL

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

(2018) Matthew R. Janes et al.   CELL

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

(2018) Liqin Wang et al.   CELL

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

(2018) Lorenzo Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma

(2018) Liang Zhang et al.   Future Oncology

xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression

(2018) Xiangming Ji et al.   ONCOGENE

Metabolic rewiring in mutant Kras lung cancer

(2017) Emma M. Kerr et al.   FEBS Journal

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

(2017) Pasi A. Jänne et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression

(2017) Delin Chen et al.   MOLECULAR CELL

SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate

(2016) Chi Chun Wong et al.   GASTROENTEROLOGY

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities

(2016) Emma M. Kerr et al.   NATURE

Metabolic Dependencies in RAS-Driven Cancers

(2015) A. C. Kimmelman   CLINICAL CANCER RESEARCH

SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma

(2015) Stephanie M. Robert et al.   Science Translational Medicine

A small molecule that induces reactive oxygen species via cellular glutathione depletion

(2014) Tatsuro Kawamura et al.   BIOCHEMICAL JOURNAL

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition

(2014) P. Ye et al.   MOLECULAR AND CELLULAR BIOLOGY

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Targeting RAS–ERK signalling in cancer: promises and challenges

(2014) Ahmed A. Samatar et al.   NATURE REVIEWS DRUG DISCOVERY

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Cooperativity of Oncogenic K-Ras and Downregulated p16/INK4A in Human Pancreatic Tumorigenesis

(2014) Zhe Chang et al.   PLoS One

Antioxidants Accelerate Lung Cancer Progression in Mice

(2014) V. I. Sayin et al.   Science Translational Medicine

Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis

(2014) Scott J Dixon et al.   eLife

Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target

(2013) Luika A. Timmerman et al.   CANCER CELL

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway

(2013) Jaekyoung Son et al.   NATURE

MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors

(2012) A. B. Turke et al.   CANCER RESEARCH

Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death

(2012) Scott J. Dixon et al.   CELL

Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism

(2012) Haoqiang Ying et al.   CELL

PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress

(2012) T Verfaillie et al.   CELL DEATH AND DIFFERENTIATION

Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors

(2011) Thomas De Raedt et al.   CANCER CELL

K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis

(2011) Yumin Hu et al.   CELL RESEARCH

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

(2011) Gina M. DeNicola et al.   NATURE

Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity

(2010) F. Weinberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FiehnLib: Mass Spectral and Retention Index Libraries for Metabolomics Based on Quadrupole and Time-of-Flight Gas Chromatography/Mass Spectrometry

(2009) Tobias Kind et al.   ANALYTICAL CHEMISTRY

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

(2009) Michel DuPage et al.   Nature Protocols

The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance

(2008) M Lo et al.   BRITISH JOURNAL OF CANCER

Small interfering RNA–mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema

(2008) Nicolai E Savaskan et al.   NATURE MEDICINE